MAGENTA THERAPEUTICS INC (MGTA) Fundamental Analysis & Valuation

NASDAQ:MGTA • US55910K1088

Current stock price

0.6996 USD
-0.06 (-7.74%)
Last:

This MGTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MGTA Profitability Analysis

1.1 Basic Checks

  • In the past year MGTA has reported negative net income.
  • In the past year MGTA has reported a negative cash flow from operations.
MGTA Yearly Net Income VS EBIT VS OCF VS FCFMGTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

  • MGTA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGTA Yearly ROA, ROE, ROICMGTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MGTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGTA Yearly Profit, Operating, Gross MarginsMGTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MGTA Health Analysis

2.1 Basic Checks

  • MGTA has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for MGTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MGTA Yearly Shares OutstandingMGTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
MGTA Yearly Total Debt VS Total AssetsMGTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -8.66, we must say that MGTA is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -8.66, MGTA is not doing good in the industry: 77.59% of the companies in the same industry are doing better.
  • There is no outstanding debt for MGTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.66
ROIC/WACCN/A
WACCN/A
MGTA Yearly LT Debt VS Equity VS FCFMGTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 19.49 indicates that MGTA has no problem at all paying its short term obligations.
  • MGTA has a Current ratio of 19.49. This is amongst the best in the industry. MGTA outperforms 93.08% of its industry peers.
  • MGTA has a Quick Ratio of 19.49. This indicates that MGTA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of MGTA (19.49) is better than 93.08% of its industry peers.
Industry RankSector Rank
Current Ratio 19.49
Quick Ratio 19.49
MGTA Yearly Current Assets VS Current LiabilitesMGTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MGTA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.98% over the past year.
EPS 1Y (TTM)12.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, MGTA will show a small growth in Earnings Per Share. The EPS will grow by 6.46% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.37%
EPS Next 2Y41.98%
EPS Next 3Y26.32%
EPS Next 5Y6.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MGTA Yearly Revenue VS EstimatesMGTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 50M 100M 150M 200M
MGTA Yearly EPS VS EstimatesMGTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

2

4. MGTA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MGTA. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 34.29, MGTA can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MGTA indicates a rather cheap valuation: MGTA is cheaper than 94.73% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, MGTA is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 34.29
MGTA Price Earnings VS Forward Price EarningsMGTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGTA Per share dataMGTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MGTA's earnings are expected to grow with 26.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.98%
EPS Next 3Y26.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MGTA Dividend Analysis

5.1 Amount

  • No dividends for MGTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MGTA Fundamentals: All Metrics, Ratios and Statistics

MAGENTA THERAPEUTICS INC

NASDAQ:MGTA (9/11/2023, 8:06:21 PM)

0.6996

-0.06 (-7.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)11-01
Inst Owners190.47%
Inst Owner Change-75.34%
Ins Owners339.14%
Ins Owner Change0%
Market Cap2.65M
Revenue(TTM)N/A
Net Income(TTM)-68.69M
Analysts43.33
Price Target1.02 (45.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)29.71%
Min EPS beat(2)-14.78%
Max EPS beat(2)74.2%
EPS beat(4)2
Avg EPS beat(4)11.93%
Min EPS beat(4)-23.46%
Max EPS beat(4)74.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)-74.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 34.29
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.04
P/tB 0.04
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)0.02
Fwd EY2.92%
FCF(TTM)-19.27
FCFYN/A
OCF(TTM)-19.16
OCFYN/A
SpS0
BVpS19.68
TBVpS19.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.68%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.49
Quick Ratio 19.49
Altman-Z -8.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)33.04%
Cap/Depr(5y)227.4%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.76%
EPS Next Y34.37%
EPS Next 2Y41.98%
EPS Next 3Y26.32%
EPS Next 5Y6.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.38%
OCF growth 3YN/A
OCF growth 5YN/A

MAGENTA THERAPEUTICS INC / MGTA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MAGENTA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to MGTA.


What is the valuation status for MGTA stock?

ChartMill assigns a valuation rating of 2 / 10 to MAGENTA THERAPEUTICS INC (MGTA). This can be considered as Overvalued.


Can you provide the profitability details for MAGENTA THERAPEUTICS INC?

MAGENTA THERAPEUTICS INC (MGTA) has a profitability rating of 0 / 10.


Can you provide the financial health for MGTA stock?

The financial health rating of MAGENTA THERAPEUTICS INC (MGTA) is 7 / 10.